Why Consumer Safety Must Be the Cornerstone of Cannabis Industry Growth
Consumer safety is the cornerstone of any legitimate industry, yet the cannabis sector remains fragmented in its adoption of standardized manufacturing practices comparable to those in the food, dietary supplement, and pharmaceutical industries. While legalization has expanded consumer access, regulatory oversight has fallen short in establishing consistent processing standards, leaving concerning gaps in consumer protection. For the cannabis industry to achieve sustainable success, it must embrace genuine current Good Manufacturing Practice (cGMP) compliance—the rigorous FDA-mandated protocols that govern food, dietary supplements, and pharmaceuticals. These standards are essential for ensuring product safety, consistency, and transparency—fundamental pillars of public health and consumer trust.
The Need for cGMP Standards in Cannabis
New York serves as both a model of progress and a case study in regulatory shortcomings. As one of the fastest-growing cannabis markets, the state has mandated that cannabis processors comply with FDA cGMP standards—a crucial step toward aligning cannabis manufacturing with established consumer safety protocols. However, despite these intentions, the Office of Cannabis Management (OCM) has failed to provide clear, enforceable guidelines, leaving consumer protections on par with other cannabis-legal states—which, in practice, remain dangerously inadequate.
cGMP compliance in food processing equipment and botanical extraction is highly specialized, drawing from multiple authoritative guidelines to address industry-specific complexities. While FDA standards provide broad frameworks for safety and quality across sectors, they lack the precision necessary for cannabis-specific processes such as converting raw plant material into extracts, edibles, tinctures, and vape products. Given that cannabis is a consumable product, it should be subject to the same rigorous manufacturing regulations as any other ingestible or inhalable substance.
This regulatory void leaves cannabis manufacturers operating with insufficient oversight, increasing the risks of contamination, product inconsistency, and unsafe consumer experiences. The absence of clear cGMP enforcement not only erodes consumer confidence but also prevents New York from setting a meaningful national precedent for cannabis safety and compliance.
Filling the Regulatory Gap with Industry Leadership
Despite these regulatory shortcomings, some cannabis processors are taking proactive steps to ensure consumer safety. In the Bronx, ProXtracts became the first Tier 1 Cannabis Processor Licensee in New York City, recognizing the importance of GMP compliance. To meet the highest standards of safety and quality, ProXtracts selected Prodigy Processing Solutions as its exclusive hydrocarbon extraction equipment provider.
This partnership highlights how processors can implement cGMP-compliant systems to safeguard product integrity, even without detailed state guidance. By partnering with an equipment manufacturer specializing in cGMP-compliant systems, ProXtracts has set a precedent for how cannabis processors can achieve pharmaceutical-grade quality despite lacking clear regulatory direction.
Ensuring that product-contact materials meet stringent safety standards—verified through Material Test Reports (MTRs) and traceability records—is critical. High-quality materials, such as 316L stainless steel, prevent corrosion and microbial buildup, keeping products safe and uncontaminated. Substandard materials degrade faster, releasing particles into cannabis extracts, posing a physical hazard to consumers. Regulators must enforce standards that prevent these risks rather than leaving businesses to self-regulate.
By incorporating pharmaceutical-grade extraction equipment built to FDA cGMP standards into its operations, ProXtracts is protecting consumers and positioning itself—and the broader New York market—for the future of the cannabis industry.
Consumer Trust Starts with cGMP Compliance
Without clear and enforceable cGMP standards, consumers remain vulnerable to contaminated products, misleading labeling, and inconsistent quality. The industry must acknowledge that cGMP compliance is not just a bureaucratic requirement—it is essential for building trust and positioning cannabis as a legitimate sector within the broader life sciences industry.
As Donald Riker, president at healthcare consultancy On Point Advisors, once said, “Manufacturing failures emerge from the line; quality failures emerge from the boardroom” (Fierce Pharma, April 5, 2011), emphasizing the responsibility of industry leaders to implement rigorous safety measures before products reach consumers.
The Consequences of Weak Oversight
Weak regulatory enforcement has resulted in serious consequences. In 2024, Missouri regulators issued the largest cannabis recall in U.S. history, pulling over 132,000 products from the market due to non-compliant lab testing and improper tracking (MDCR, August 6, 2024).
Missouri’s recalls were not isolated events. In California, state regulators took significant enforcement actions in 2024, issuing 63 product recall notices affecting 259 products and nearly 25,000 individual units. Additionally, 481 embargoes removed cannabis products from circulation due to contamination concerns, including pesticides and other harmful substances (MJBizDaily, Feb. 5, 2025).
These recalls highlight a dangerous reality—without proper oversight, unsafe products remain in circulation. If state agencies fail to enforce meaningful compliance measures, the burden of ensuring product safety shifts unfairly to consumers, who lack the tools to verify what they’re purchasing. The volume of recalls and embargoes across markets underscores the need for cGMP enforcement at the state and federal levels to prevent widespread contamination, protect consumers, and ensure cannabis products meet the same safety expectations as other ingestible and inhalable goods.
Bridging the Gap Between Cannabis & Pharma
The push for pharmaceutical-grade production standards is shaping the future of cannabis manufacturing. While federal rescheduling remains uncertain, operators who adopt cGMP standards today will be best positioned for future regulatory alignment and global market opportunities.
Pharmaceutical companies require strict manufacturing consistency. As cannabis evolves into a mainstream consumer product, producers that align with these standards will be prepared for market expansion and regulatory shifts. By implementing FDA-compliant practices, validated production methods, and pharmaceutical-grade equipment, cannabis processors can strengthen consumer confidence while laying the foundation for broader industry adoption of cGMP protocols.
Read More: Difference Between Hemp Analogs
A Call to Action for Regulators
To advance cannabis industry standards, regulators must collaborate with industry leaders to develop clear, science-based cGMP requirements that are both enforceable and actionable, with consumer safety as the guiding principle.
Consumers deserve transparency, and businesses require a regulatory framework that establishes definitive expectations rather than vague, inconsistent guidelines. Without a structured approach, the industry remains vulnerable to safety lapses that undermine public trust.
The long-term viability of the cannabis industry hinges on the adoption of these standards—not merely as a regulatory obligation, but as an ethical responsibility to the consumers it serves.
And if a commitment to consumer protection alone is not incentive enough, the financial and legal risks of noncompliance should be. Avoiding costly recalls and product liability lawsuits should serve as a compelling motivator for cannabis processors. The future of the cannabis industry depends on its ability to meet the same safety and quality expectations that consumers demand from any other consumable product.
The post Why Consumer Safety Must Be the Cornerstone of Cannabis Industry Growth appeared first on Cannabis & Tech Today.